10-Q 1 elmd210662_10q.htm FORM 10-Q FOR QUARTER ENDED MARCH 31, 2021

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File No.: 001-34839

Electromed, Inc.

(Exact Name of Registrant as Specified in its Charter)

Minnesota		41-1732920
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

500 Sixth Avenue NW New Prague, Minnesota		56071
(Address of principal executive offices)		(Zip Code)

(952) 758-9299

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, $0.01 par value		ELMD		NYSE American LLC
(Title of each class)		(Trading Symbol(s))		(Name of each exchange on which registered)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☑

Smaller reporting company ☑

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

There were [8,637,420] shares of Electromed, Inc. common stock, par value $0.01 per share, outstanding as of the close of business on May 7, 2021.

Electromed, Inc.

Index to Quarterly Report on Form 10-Q

			Page

PART I – FINANCIAL INFORMATION

	Item 1.	Financial Statements	1
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	18
	Item 4.	Controls and Procedures	18

PART II – OTHER INFORMATION

	Item 1.	Legal Proceedings	18
	Item 1A.	Risk Factors	18
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
	Item 3.	Defaults Upon Senior Securities	19
	Item 4.	Mine Safety Disclosures	19
	Item 5.	Other Information	19
	Item 6.	Exhibits	19

PART I – FINANCIAL INFORMATION

Item 1.

Financial Statements.

Electromed, Inc.

Condensed Balance Sheets

	March 31, 2021		June 30, 2020
	(Unaudited)
Assets
Current Assets
Cash	$	12,500,688	$	10,479,150
Accounts receivable (net of allowances for doubtful accounts of $45,000)		16,236,661		12,940,677
Contract assets		557,531		902,619
Inventories, net		2,256,012		3,084,620
Prepaid expenses and other current assets		483,399		353,318
Income tax receivable		253,891		262,155
Total current assets		32,288,182		28,022,539
Property and equipment, net		3,526,935		3,788,469
Finite-life intangible assets, net		602,430		598,389
Other assets		100,016		80,166
Deferred income taxes		653,000		755,000
Total assets	$	37,170,563	$	33,244,563

Liabilities and Shareholders’ Equity
Current Liabilities
Current maturities of other long-term liabilities	$	40,681	$	72,328
Accounts payable		1,023,603		555,510
Accrued compensation		2,273,415		1,404,497
Warranty reserve		740,000		740,000
Other accrued liabilities		160,551		214,045
Total current liabilities		4,238,250		2,986,380
Other long-term liabilities		59,702		8,868
Total liabilities		4,297,952		2,995,248

Commitments and Contingencies

Shareholders’ Equity
Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,637,420 and 8,567,834 shares issued and outstanding, respectively		86,374		85,678
Additional paid-in capital		17,140,274		16,480,134
Retained earnings		15,645,963		13,683,503
Total shareholders’ equity		32,872,611		30,249,315
Total liabilities and shareholders’ equity	$	37,170,563	$	33,244,563

See Notes to Condensed Financial Statements (Unaudited).

Electromed, Inc.

Condensed Statements of Operations (Unaudited)

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Net revenues	$	8,786,972	$	8,743,897	$	26,287,217	$	25,593,337
Cost of revenues		2,086,120		2,150,347		5,912,900		5,981,931
Gross profit		6,700,852		6,593,550		20,374,317		19,611,406

Operating expenses
Selling, general and administrative		6,050,666		5,288,485		16,489,871		15,148,344
Research and development		407,199		391,962		1,395,755		634,376
Total operating expenses		6,457,865		5,680,447		17,885,626		15,782,720
Operating income		242,987		913,103		2,488,691		3,828,686
Interest income, net		9,784		34,171		28,769		111,200
Net income before income taxes		252,771		947,274		2,517,460		3,939,886

Income tax expense		29,000		294,000		555,000		1,087,000

Net income	$	223,771	$	653,274	$	1,962,460	$	2,852,886

Income per share:

Basic	$	0.03	$	0.08	$	0.23	$	0.34

Diluted	$	0.03	$	0.07	$	0.22	$	0.33

Weighted-average common shares outstanding:
Basic		8,576,523		8,403,154		8,565,839		8,390,916
Diluted		8,907,045		8,880,794		8,921,494		8,759,493

See Notes to Condensed Financial Statements (Unaudited).

Electromed, Inc.

Condensed Statements of Cash Flows (Unaudited)

	Nine Months Ended March 31,
	2021			2020
Cash Flows From Operating Activities
Net income	$	1,962,460		$	2,852,886
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		358,660			469,784
Amortization of finite-life intangible assets		98,785			90,863
Share-based compensation expense		755,999			676,558
Deferred income taxes		102,000			27,000
Loss on disposal of property and equipment		-			1,294
Changes in operating assets and liabilities:
Accounts receivable		(3,295,984	)		(530,360	)
Contract assets		345,088			(150,995	)
Inventories		838,747			(13,852	)
Prepaid expenses and other assets		(68,616	)		50,329
Income tax receivable		8,264			(409,064	)
Income tax payable		-			(288,511	)
Accounts payable and accrued liabilities		1,219,429			136,361
Net cash provided by operating activities		2,324,832			2,912,293

Cash Flows From Investing Activities
Expenditures for property and equipment		(105,472	)		(752,875	)
Expenditures for finite-life intangible assets		(102,659	)		(97,460	)
Net cash used in investing activities		(208,131	)		(850,335	)

Cash Flows From Financing Activities
Issuance of common stock upon exercise of options		45,669			63,423
Taxes paid on net share settlement of stock option exercises		(140,832	)		-
Net cash (used in) provided by financing activities		(95,163	)		63,423
Net increase in cash		2,021,538			2,125,381
Cash
Beginning of period		10,479,150			7,807,928
End of period	$	12,500,688		$	9,933,309

See Notes to Condensed Financial Statements (Unaudited).

Electromed, Inc.

Condensed Statements of Shareholders’ Equity (Unaudited)

	Common Stock
	Shares		Amount		Additional Paid- in Capital			Retained Earnings		Total Shareholders’ Equity
Balance at June 30, 2019		8,408,351	$	84,084	$	16,127,826		$	9,522,064	$	25,733,974

Net income		–		–		–			1,014,556		1,014,556
Issuance of restricted stock		32,500		325		(325	)		–		–
Issuance of common stock upon exercise of options		5,000		50		12,990			–		13,040
Share-based compensation expense		–		–		209,954			–		209,954
Balance at September 30, 2019		8,445,851		84,459		16,350,445			10,536,620		26,971,524

Net income		–		–		–			1,185,056		1,185,056
Issuance of restricted stock		15,000		150		(150	)		–		–
Issuance of common stock upon exercise of options		17,597		175		62,721			–		62,896
Share-based compensation expense		–		–		234,304			–		234,304
Balance at December 31, 2019		8,478,448		84,784		16,647,320			11,721,676		28,453,780

Net income		–		–		–			653,274		653,274
Issuance of common stock upon exercise of options		5,337		54		(12,567	)		–		(12,513	)
Share-based compensation expense		–		–		232,300			–		232,300
Balance at March 31, 2020		8,483,785	$	84,838	$	16,867,053		$	12,374,950	$	29,326,841

	Common Stock
	Shares		Amount		Additional Paid- in Capital			Retained Earnings		Total Shareholders’ Equity
Balance at June 30, 2020		8,567,834	$	85,678	$	16,480,134		$	13,683,503	$	30,249,315

Net income		–		–		–			535,262		535,262
Issuance (forfeiture) of restricted stock		19,090		191		(191	)		–		–
Issuance of common stock upon exercise of options		19,256		193		(193	)		–		–
Taxes paid on stock option exercised on a net basis		–		–		(119,664	)		–		(119,664	)
Share-based compensation expense		–		–		191,103			–		191,103
Balance at September 30, 2020		8,606,180		86,062		16,551,189			14,218,765		30,856,016

Net income		–		–		–			1,203,427		1,203,427
Issuance (forfeiture) of restricted stock		18,000		180		(180	)		–		–
Issuance of common stock upon exercise of options		10,865		108		45,561			–		45,669
Taxes paid on net share settlement of stock option exercises		–		–		(10,051	)		–		(10,051	)
Share-based compensation expense		–		–		238,673			–		238,673
Balance at December 31, 2020		8,635,045		86,350		16,825,192			15,422,192		32,333,734

Net income		–		–		–			223,771		223,771
Issuance of common stock upon exercise of options		2,375		24		(24)			–		–
Taxes paid on net share settlement of stock option exercises		–		–		(11,117	)		–		(11,117	)
Share-based compensation expense		–		–		326,223			–		326,223
Balance at March 31, 2021		8,637,420	$	86,374	$	17,140,274		$	15,645,963	$	32,872,611

See Notes to Condensed Financial Statements (Unaudited).

Electromed, Inc.

Notes to Condensed Financial Statements
(Unaudited)

Note 1. Interim Financial Reporting

Basis of presentation: Electromed, Inc. (the “Company”) develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest Wall Oscillation (“HFCWO”) therapy in pulmonary care for patients of all ages. The Company markets its products in the U.S. to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also sells internationally both directly and through distributors. International sales were approximately $297,000 and $455,000 for the nine months ended March 31, 2021 and 2020, respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment.

The accompanying unaudited Condensed Financial Statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. In the opinion of management, the accompanying unaudited Condensed Financial Statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. GAAP for annual reports. This interim report should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (“fiscal 2020”).

Impacts of COVID-19 on the Company’s business:

The impact of the COVID-19 pandemic on the Company’s business remains uncertain and its effects on its operational and financial performance will depend in large part on future developments, which cannot be reasonably estimated at this time. Such future developments include, but are not limited to, the duration, scope and severity of the COVID-19 pandemic in geographic areas the Company operates or in which its patients live, actions taken to contain or mitigate its impact, the impact on governmental healthcare programs and budgets, the development and distribution of treatments or vaccines, and the resumption of widespread economic activity. Due to the inherent uncertainty of the unprecedented and rapidly evolving situation, the Company is unable to predict with confidence the likely impact of the COVID-19 pandemic on its future operations. For a more detailed discussion see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part I, Item 2 of this Quarterly Report on Form 10-Q.

A summary of the Company’s significant accounting policies follows:

Use of estimates. Management uses estimates and assumptions in preparing the unaudited Condensed Financial Statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its unaudited Condensed Financial Statements include revenue recognition and the related estimation of variable consideration, allowance for doubtful accounts, inventory obsolescence, share-based compensation and its warranty liability.

Net income per common share. Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive was 52,017 and zero for the three months ended March 31, 2021 and 2020, respectively, and were 52,017 and 134,100 for the nine months ended March 31, 2021 and 2020, respectively.

Note 2. Revenues

Revenue is measured based on consideration specified in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, including non-cash consideration, consideration paid or payable to customers and significant financing components. Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer, as further described below under Performance obligations and transaction price.

Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the individual good or service is distinct (i.e., the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement). If an arrangement includes multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated standalone selling price, unless discounts or variable consideration is attributable to one or more but not all the performance obligations. Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs under Accounting Standards Codification (“ASC”) 340-40, “Other Assets and Deferred Costs” (“ASC 340”), or other applicable guidance are met.

The Company includes shipping and handling fees in net revenues. Shipping and handling costs associated with the shipment of the Company’s SmartVest® Airway Clearance System (“SmartVest System”) after control has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues in the Condensed Statements of Operations.

The timing of revenue recognition, billings and cash collections results in accounts receivable on the Condensed Balance Sheets as further described below under Accounts receivable and Contract assets.

Disaggregation of revenues. In the following table, net revenues are disaggregated by market:

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Home Care	$	8,162,677	$	7,834,094	$	24,528,898	$	22,994,856
Institutional		442,558		608,519		1,029,244		1,726,868
Home Care Distributor		105,816		164,564		432,346		415,933
International		75,921		136,720		296,729		455,680
Total	$	8,786,972	$	8,743,897	$	26,287,217	$	25,593,337

In the following table, net home care revenue is disaggregated by payer type:

	Three Months Ended March 31,				Nine Months Ended March 31,
	2021		2020		2021		2020
Commercial	$	3,110,205	$	3,486,387	$	9,211,437	$	9,474,517
Medicare		4,622,112		3,818,185		14,224,173		11,281,858
Medicaid		316,375		300,664		669,187		1,432,074
Other		113,985		228,858		424,101		806,407
Total	$	8,162,677	$	7,834,094	$	24,528,898	$	22,994,856

Revenues in the Company’s home care, home care distributor, and international markets are recognized at a point in time when control passes to the customer upon product shipment or delivery. Revenues in the Company’s institutional market include sales recognized at a point in time upon shipment or delivery as well as revenues recognized over time under operating leases.

Performance obligations and transaction price. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under ASC 606, “Revenue From Contracts With Customers” (“ASC 606”). A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s performance obligations and the timing or method of revenue recognition in each of the Company’s markets are discussed below:

Home care market. In the Company’s home care market, its customers are patients who use the SmartVest System. The various models of the SmartVest System are comprised of three main components - a generator, a vest and a connecting hose - that are sold together as an integrated unit. Accordingly, in contracts within the home care market, the Company regards the SmartVest System to be a single performance obligation.

The Company makes available to its home care patients limited post-sale services that are not material in the context of the contracts, either individually or taken together, and therefore does not consider them to be performance obligations. The costs associated with the services are accrued and expensed when the related revenues are recognized. As such, transactions in the home care market consist of a single performance obligation: the SmartVest System.

Home care patients generally will rely on third-party payers, including commercial payers and governmental payers such as Medicare, Medicaid and the U.S. Department of Veterans Affairs to cover and reimburse all or part of the cost of the SmartVest System. The third-party payers’ reimbursement programs fall into three types, distinguished by the differences in the timing of payments from the payer, consisting of either (i) outright sale, in which payment is received from the payer based on standard terms, (ii) capped installment sale, under which the SmartVest System is sold for a series of payments that are capped not to exceed a prescribed or negotiated amount over a period of time or (iii) installment sale, under which the SmartVest System is paid for over a period of several months as long as the patient continues to use the SmartVest System.

Regardless of the type of transaction, provided criteria for an enforceable contract are met, it is the Company’s long-standing business practice to regard all home care agreements as transferring control to the patient upon shipment or delivery, in spite of possible payment cancellation under government or commercial programs where the payer is controlling the payment over specified time periods. For home care sales that feature installment payments, the ultimate amount of consideration received from Medicare, Medicaid or commercial payers can be significantly less than expected if the contract is terminated due to changes in the patient’s status, including insurance coverage, hospitalization, death or otherwise becoming unable to use the SmartVest System. However, once delivered to a patient who needs the SmartVest System, the patient is under no obligation to return the SmartVest System should payments be terminated as a result of the described contingencies. As a result, the Company’s product sales qualify for point in time revenue recognition. Control transfers to the patient, and revenue is recognized, upon shipment of the SmartVest System. At this point, physical possession and the significant risks and rewards of ownership are transferred to the patient and either a current or future right to payment is triggered, as further discussed under Accounts receivable and Contract assets below.

The Company’s contractually stated transaction prices in the home care market are generally set by the terms of the contracts negotiated with insurance companies or by government programs. The transaction price for the Company’s products may be further impacted by variable consideration. ASC 606 requires the Company to adjust the transaction price at contract inception and throughout the contract duration for the estimated value of payments to be received from insurance payers based on historical experience and other available information, subject to the constraint on estimates of variable consideration. Transactions requiring estimates of variable consideration primarily include (i) capped installment payments, which are subject to the third-party payer’s termination due to changes in insurance coverage, death or the patient’s discontinued use of the SmartVest System, (ii) contracts under appeal and (iii) patient responsibility amounts for deductibles, coinsurance, copays and other similar payments.

Although estimates may be made on a contract-by-contract basis, whenever possible, the Company uses all available information, including historical collection patterns, to estimate variable consideration for portfolios of contracts. The Company’s estimates of variable consideration consist of amounts it may receive from insurance providers in excess of its initial revenue estimate due to patients meeting deductibles or coinsurance during the payment duration, changes to a patient’s insurance status, changes in an insurance allowable, claims in appeals with Medicare and amounts received directly from patients for their allowable or coinsurance. The Company believes it has representative historical information to estimate the amount of variable consideration in relevant portfolios considering the significant experience it has with each portfolio and the similarity of patient accounts within a portfolio. The analysis includes steps to ensure that revenue recognized on a portfolio basis does not result in a material difference when compared with an individual contract approach. The Company also leverages its historical experience and all available relevant information for each portfolio of contracts to minimize the risk its estimates used to arrive at the transaction price will result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur.

For example, for contracts in which the Company believes the criteria for reimbursement under government or commercial payer contracts have been met but for which coverage is unconfirmed or payments are under appeal, the Company has significant observable evidence of relatively consistent claims recovery experience over the prior three to five years. The Company believes the low volatility in historical claims approval rates for populations of patients whose demographics are similar to those of current patients provides reliable predictive value in arriving at estimates of variable consideration in such contracts. Similarly, historical payment trends for recovery of claims subject to payer installments and payments from patients have remained relatively consistent over the past five years. No significant changes in patient demographics or other relevant factors have occurred that would limit the predictive value of such payment trends in estimating variable consideration for current contracts. As a result, the Company believes its estimates of variable consideration are generally not subject to the risk of significant revenue reversal.

For each type of variable consideration discussed above, there are a large number of contracts with similar characteristics with a wide range of possible transaction prices. For that reason, the Company uses the probability-weighted expected value method provided under ASC 606 to estimate variable consideration.

The Company often receives payment from third-party payers for the SmartVest System sales over a period of time that may exceed one year. Despite these extended payment terms, no significant financing component is deemed to exist because the purpose of such terms is not to provide financing to the patient, the payer or the Company. Rather, the extended payment terms are mandated by the government or commercial insurance programs; the fundamental purpose of which is to avoid paying the full purchase price of equipment that may potentially be used by the patient for only a short period of time.

Home care distributors. Sales to distributors, who sell direct to patients, are made at fixed contract prices and may include tiered pricing structures or volume-based rebates which offer more favorable pricing once certain volumes are achieved per the negotiated contract. The distributor’s purchases accumulate to give the distributor a right to a higher discount on purchases in excess of the specified level within the contract period. As a result, to the extent the Company expects the distributor to exceed the specified volume of purchases in the annual period, it recognizes revenue at a blended rate based on estimated total annual volume and sales revenue. This effectively defers a portion of the transaction price on initial purchases below the specified volumes for recognition when the higher discount is earned on purchases in excess of specified volumes. Transfer of control of the products occurs upon shipment or delivery to the distributor, as applicable.

Institutional market. The Company’s institutional sales are made to hospitals and home health care centers, pulmonary rehabilitation centers and other clinics. Sales to these institutions are negotiated with the individual institution or with group purchasing organizations, with payments received directly from the institution. No insurance reimbursement is involved. Generators are either sold or leased to the institutions and associated hoses and wraps (used in institutional settings rather than vests) are sold separately. Accordingly, each product is distinct and considered a separate performance obligation in sales to institutional customers. The agreements with institutions fall into two main types, distinguished by differences in the timing of transfer of control and timing of payments:

●

Outright sale – Under these transactions, the Company sells its products for a prescribed or negotiated price. Transfer of control of the product, and associated revenue recognition, occurs at the time of shipment and payment is made within normal credit terms, usually within 30 days.

●

Rental – Under these transactions, the customer obtains a right to use the product for a period of time in exchange for consideration as usage occurs. These transactions are treated as operating leases and revenue is recognized ratably over the applicable rental period. Lease revenue recognized during the nine months ended March 31, 2021 and 2020 was zero and approximately $6,000, respectively.

International market. Sales to international markets are made directly to a number of independent distributors at fixed contract prices that are not subject to further adjustments for variable consideration. Transfer of control of the products occurs upon shipment or delivery to the distributor, as applicable.

Product warranty. The Company offers warranties on its products. These warranties are assurance type warranties not sold on a standalone basis or are otherwise considered immaterial in the context of the contract, and therefore are not considered distinct performance obligations under ASC 606. The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product is sold.

Accounts receivable. Accounts receivable include amounts billed to customers and third-party payers, for which only the passage of time is required before payment of consideration is due. Amounts due are stated at their net estimated realizable value.

Contract assets. Contract assets include amounts recognized as revenue that are estimates of variable consideration for Medicare appeals where the final determination of the insurance coverage amount is dependent on future approval of an appeal, or when the consideration due to the Company is dependent on a future event such as the patient meeting a deductible prior to the Company’s claim being processed by the payer. Contract assets are classified as current as amounts will turn into accounts receivable and be collected during the Company’s normal business operating cycle. Contract assets are reclassified to accounts receivable when the right to receive payment is unconditional.

Incremental costs to obtain a contract. Sales incentives paid to sales representatives are eligible for capitalization as they are incremental costs that would not have been incurred without entering into a specific sales arrangement and are recoverable through the expected margin on the transaction. However, the recovery period is less than one year as the performance obligation is satisfied upon shipment or delivery. Consequently, the Company applies the practical expedient provided by ASC 340 and expenses sales incentives as incurred. These costs are included in selling, general and administrative expenses in the Condensed Statements of Operations.

Contract balances. The following table provides information about accounts receivable and contracts assets from contracts with customers:

	March 31, 2021		June 30, 2020
Receivables, included in “Accounts receivable, net of allowance for doubtful accounts”	$	16,236,661	$	12,940,677
Contract assets	$	557,531	$	902,619

Significant changes in contract assets during the period are as follows:

	Nine Months Ended March 31, 2021			Fiscal Year Ended June 30, 2020
	Increase (decrease)			Increase (decrease)
Contract assets, beginning	$	902,619		$	995,847
Reclassification of contract assets to accounts receivable		(1,180,558	)		(1,857,818	)
Contract assets recognized		835,335			1,733,835
Increase as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period		135			30,755
Contract assets, ending	$	557,531		$	902,619

Note 3. Inventories

The components of inventory were as follows:

	March 31, 2021			June 30, 2020
Parts inventory	$	1,754,396		$	2,270,766
Work in process		62,033			126,726
Finished goods		609,805			826,740
Estimated inventory to be returned		129,778			150,388
Less: Reserve for obsolescence		(300,000	)		(290,000	)
Total	$	2,256,012		$	3,084,620

Note 4. Finite-life Intangible Assets

The carrying value of patents and trademarks includes the original cost of obtaining the patents, periodic renewal fees and other costs associated with maintaining and defending patent and trademark rights. Patents and trademarks are amortized over their estimated useful lives, generally 15 and 12 years, respectively. Accumulated amortization was approximately $1,216,000 and $1,119,000 at March 31, 2021 and June 30, 2020, respectively. The activity and balances of finite-life intangible assets were as follows:

	Nine Months Ended			Fiscal Year Ended
	March 31, 2021			June 30, 2020
Balance, beginning	$	598,389		$	581,413
Additions		102,826			138,739
Amortization expense		(98,785	)		(121,763	)
Balance, ending	$	602,430		$	598,389

Note 5. Warranty Liability

The Company provides a lifetime warranty on its products to the prescribed patient for sales within the U.S. and a three-year warranty for all institutional sales and sales to individuals outside the U.S. The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is shipped. Factors that affect the Company’s warranty liability include the number of units shipped, historical and anticipated rates of warranty claims, the product’s useful life and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amounts as necessary.

Changes in the Company’s warranty liability were approximately as follows:

	Nine Months Ended March 31, 2021			Fiscal Year Ended June 30, 2020
Warranty reserve, beginning	$	740,000		$	810,000
Accrual for products sold		127,500			79,000
Expenditures and costs incurred for warranty claims		(127,500	)		(149,000	)
Warranty reserve, ending	$	740,000		$	740,000

Note 6. Income Taxes

Income tax expense was estimated at $29,000 and $555,000 and the effective tax rate was 11.5% and 22.0% for the three and nine months ended March 31, 2021, respectively. Estimated income tax expense for the three months ended March 31, 2021 included a $37,000 discrete tax benefit as a result of lower federal and state taxes than what was originally estimated in the Company’s fiscal 2020 tax provision. The net impact of this discrete event decreased the estimated effective tax rates by 14.6% during the three months ended March 31, 2021. Estimated income tax expense for the nine months ended March 31, 2021 included a $37,000 discrete tax benefit as a result of lower federal and state taxes than what was originally estimated in the Company’s fiscal 2020 tax provision and a $32,000 discrete tax benefit related to the exercise of stock options. The net impact of these discrete events decreased the estimated effective tax rates by 2.7% during the nine months ended March 31, 2021.

Income tax expense was estimated at $294,000 and $1,087,000, and the effective tax rate was 31.0% and 27.6%, for the three and nine months ended March 31, 2020, respectively. Estimated income tax expense for the nine months ended March 31, 2020 included a $30,000 discrete tax expense as a result of higher federal and state taxes than what was originally estimated in the Company’s tax provision for its fiscal year ended June 30, 2019, and a $13,000 discrete tax benefit related to the exercise of stock options. The net impact of these discrete events increased the estimated effective tax rates by 0.4% during the nine months ended March 31, 2020.

Note 7. Financing Arrangements

The Company has a credit facility that provides for a revolving line of credit and a term loan. Effective December 18, 2020, the Company renewed its $2,500,000 revolving line of credit. There was no outstanding principal balance on the line of credit as of March 31, 2021 or June 30, 2020. Interest on borrowings under the line of credit, if any, accrues at the prime rate (3.25% at March 31, 2021) less 1.00% and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.00% of eligible accounts receivable and the line of credit expires on December 18, 2021, if not renewed. At March 31, 2021, the maximum $2,500,000 was eligible for borrowing. Payment obligations under the line of credit, if any, are secured by a security interest in substantially all of the tangible and intangible assets of the Company.

The documents governing the line of credit contain certain financial and nonfinancial covenants that include a minimum tangible net worth covenant of not less than $10,125,000 and restrictions on the Company’s ability to incur certain additional indebtedness or pay dividends.

Note 8. Share-Based Compensation

The Company’s share-based compensation plans are described in Note 8 of the Company’s Annual Report on Form 10-K for fiscal 2020. Share-based compensation expense was approximately $756,000 and $677,000 for the nine months ended March 31, 2021 and 2020, respectively. This expense is included in selling, general and administrative expense in the Condensed Statements of Operations. As of March 31, 2021, approximately $921,000 of total unrecognized compensation expense related to non- vested equity awards was expected to be recognized over a weighted-average period of approximately 0.8 years.

Stock Options

Stock option transactions during the nine months ended March 31, 2021 are summarized as follows:

	Number of Shares			Weighted Average Exercise Price per Share
Outstanding at June 30, 2020		590,780		$	4.34
Granted		61,017		$	14.14
Exercised		(71,150	)	$	5.09
Cancelled or Forfeited		(109,198	)	$	6.24
Outstanding at March 31, 2021		471,449		$	5.05

The following assumptions were used to estimate the fair value of stock options granted:

	Nine Months Ended March 31, 2021		Fiscal Year Ended June 30, 2020
Risk-free interest rate		0.31% - 0.59%		1.85	%
Expected term (years)		6.0		6.0
Expected volatility		283.05% - 335.33%		190.1	%

The intrinsic value of an option is the amount by which the fair value of the underlying stock exceeds its exercise price. At March 31, 2021, the weighted average remaining contractual term for all outstanding stock options was 6.1 years and their aggregate intrinsic value was $2,771,858. Outstanding at March 31, 2021 were 471,449 stock options issued to employees, of which 334,438 were vested and exercisable and had an aggregate intrinsic value of $2,326,959.

Restricted Stock

During the nine months ended March 31, 2021, the Company issued restricted stock awards to employees totaling 30,756 shares of common stock, with a vesting term of two to three years and a weighted average fair value of $12.93 per share and to directors totaling 18,000 shares of common stock, with a vesting term of six months and a weighted average fair value of $9.94 per share. There were 71,255 shares of unvested restricted stock with a weighted average fair value of $10.80 per share as of March 31, 2021.

Note 9. Commitments and Contingencies

The Company is occasionally involved in claims and disputes arising in the ordinary course of business. The Company insures certain business risks where possible to mitigate the financial impact of individual claims and establishes reserves for an estimate of any probable cost of settlement or other disposition.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited Condensed Financial Statements and related notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q, and our audited financial statements and related notes thereto included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (“fiscal 2020”).

Overview

Electromed, Inc. (“we,” “our,” “us,” “Electromed” or the “Company”) develops and provides innovative airway clearance products applying High Frequency Chest Wall Oscillation (“HFCWO”) technologies in pulmonary care for patients of all ages.

We manufacture, market and sell products that provide HFCWO, including the SmartVest® Airway Clearance System (“SmartVest System”) that includes our newest generation SmartVest SQL® and previous generation SV2100, and related products, to patients with compromised pulmonary function. The SmartVest SQL is smaller, quieter and lighter than our previous product, with enhanced programmability and ease of use. Our products are sold in both the home health care market and the institutional market for use by patients in hospitals, which we refer to as “institutional sales.” The SmartVest SQL has been sold in the domestic home care market since 2014. In 2015, we launched the SmartVest SQL into institutional and certain international markets. In June 2017, we announced the launch of the SmartVest SQL with SmartVest Connect™ wireless technology, which allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. SmartVest Connect is currently available to pediatric and cystic fibrosis patients and was made available to certain targeted adult pulmonary clinics starting in November 2017. Since 2000, we have marketed the SmartVest System and its predecessor products to patients suffering from cystic fibrosis, bronchiectasis and repeated episodes of pneumonia. Additionally, we offer our products to a patient population that includes neuromuscular disorders such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis (“ALS”), the combination of emphysema and chronic bronchitis commonly known as chronic obstructive pulmonary disease (“COPD”), and patients with post-surgical complications or who are ventilator dependent or have other conditions involving excess secretion and impaired mucus transport.

The SmartVest System is often eligible for reimbursement from major private insurance providers, health maintenance organizations (“HMOs”), state Medicaid systems, and the federal Medicare system, which we believe is an important consideration for patients considering an HFCWO course of therapy. For domestic sales, the SmartVest System may be reimbursed under the Medicare-assigned billing code (E0483) for HFCWO devices if the patient has cystic fibrosis, bronchiectasis (including chronic bronchitis or COPD that has resulted in a diagnosis of bronchiectasis), or any one of certain enumerated neuromuscular diseases, and can demonstrate that another less expensive physical or mechanical treatment did not adequately mobilize retained secretions. Private payers consider a variety of sources, including Medicare, as guidelines in setting their coverage policies and payment amounts.

Critical Accounting Policies and Estimates

For a description of our critical accounting policies, estimates and assumptions used in the preparation of our financial statements, including the unaudited Condensed Financial Statements in this Quarterly Report on Form 10-Q, see Note 1 to our unaudited Condensed Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q and Part II, Item 7, and Note 1 to our audited financial statements included in Part II, Item 8, of our Annual Report on Form 10-K for fiscal 2020.

Some of our accounting policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial statements. Such judgments are subject to an inherent degree of uncertainty. Among other factors, these judgments are based upon our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources, as appropriate. We believe the critical accounting policies that require the most significant assumptions and judgments in the preparation of our financial statements, including the unaudited Condensed Financial Statements contained in this Quarterly Report on Form 10-Q, include: revenue recognition and the estimation of variable consideration, allowance for doubtful accounts, inventory obsolescence, share-based compensation and warranty liability.

Impacts of COVID-19 on Our Business and Operations

In March 2020, the World Health Organization designated COVID-19 as a global pandemic and the U.S. Department of Health and Human Services designated COVID-19 as a public health emergency. The impact of the COVID-19 pandemic on our business remains uncertain and its effects on our operational and financial performance will depend in part on future developments, which cannot be reasonably estimated at this time. Such future developments include, but are not limited to, the duration, scope and severity of the COVID-19 pandemic in geographic areas in which we operate or in which our patients live, actions taken to contain or mitigate its impact, the impact on governmental healthcare programs and budgets, the development and distribution of treatments or vaccines, and the resumption of widespread economic activity. Due to the inherent uncertainty of the unprecedented and evolving situation, we are unable to predict with confidence the likely impact of the COVID-19 pandemic on our future operations.

The COVID-19 pandemic has created significant volatility, uncertainty and economic disruption and has negatively impacted business in our industry since March 2020. In particular, certain healthcare facilities and clinics restricted access to their clinicians, reducing patient consultations and treatments, or closed temporarily due to the COVID-19 pandemic, which reduced home care referrals and resulted in certain institutional orders being postponed. We believe that these and other responses by healthcare systems have had a negative impact on our operating results and cash flows during the third quarter of our fiscal year ending June 30, 2021 (“fiscal 2021”). During the first half of fiscal 2021, as state and local government restrictions began to ease in jurisdictions in which we operate, we observed increased patient face-to-face re-engagement with clinicians and an increased number of clinics allowing face-to-face access by our sales team. During the three months ended March 31, 2021, referrals declined early in the quarter compared to prior period due to reduced patient face-to-face interactions with clinicians, likely due to COVID-19 cases increasing as well as a desire for patients to be vaccinated before visiting healthcare facilities. Referral growth increased significantly in March compared to prior year, as we benefited from increased patient visits to clinics and greater access for our sales representatives, restrictions were further lifted, and vaccines started to become more widely administered throughout the country. Our sales team continues to utilize a hybrid sales process of virtual and face- to-face clinician interaction with strict adherence to specific clinic and healthcare system safety protocols.

We estimate that institutional revenue has been negatively impacted since the onset of the COVID-19 pandemic as hospitals and long-term care facilities have adjusted their operating protocols and procurement management.

We believe that the impact of the COVID-19 pandemic on our home care and institutional business will likely continue during the remainder of fiscal 2021. We have experienced improvement in our home care referrals and approvals for the three months ended March 31, 2021 as compared to the three months ended March 31, 2020; however, if COVID-19 infection rates increase and federal, state and local restrictions on commerce, stay-at-home orders or other restrictions on businesses are reinstated, then such measures could have a material adverse effect on our business.

We believe that the COVID-19 pandemic’s adverse impact on our operating results, cash flows and financial condition will be primarily driven by: the severity and duration of the pandemic; its impact on the U.S. healthcare system and economy; and the timing, scope and effectiveness of U.S. governmental responses to the pandemic.

We have observed some minor changes to our supply chain timelines and increased product costs, but we have not experienced any material adverse impacts on our supply chain or product costs at this time. It is possible the COVID-19 pandemic could have an adverse impact on our supply chain in the future, including impacts associated with preventive and precautionary measures that other businesses and applicable governments are taking. A reduction or interruption in any of our manufacturing processes could have a material adverse effect on our business. Any significant increases to our product costs could reduce our gross margins.

We have also taken measures to ensure the safety of our employees and to comply with applicable governmental orders. We consider our business to be essential under applicable governmental orders due primarily to our role in manufacturing and supplying needed medical devices to patients with respiratory related issues and have therefore continued to operate during the government restrictions put in place in response to the pandemic.

In response to the COVID-19 pandemic and the U.S. federal government’s declaration of a public health emergency, the Centers for Medicare & Medicaid Services (“CMS”) implemented a number of temporary rule changes and waivers to allow prescribers to best treat patients during the period of the public health emergency. These waivers are retroactively effective to March 1, 2020. Clinical indications and documentation typically required will not be enforced for respiratory related products including the SmartVest System (solely with respect to Medicare patients). The minimum documentation now requires a valid order and documentation of a respiratory related diagnosis. Face-to-face and in-person requirements for respiratory devices are being waived during such period. The CMS waiver was recently extended in conjunction with the extension of the federal public health emergency for an additional 90-day period beginning on April 21, 2021.

Results of Operations

Net Revenues

Net revenues for the three and nine months ended March 31, 2021 and 2020 are summarized in the table below (dollar amounts in thousands).

	Three Months Ended March 31,									Nine Months Ended March 31,
	2021		2020		Change					2021		2020		Change
Home care	$	8,163	$	7,834	$	329		4.2	%	$	24,529	$	22,995	$	1,534		6.7	%
Institutional		443		609		(166	)	(27.3	%)		1,029		1,727		(698	)	(40.4	%)
Home care distributor		105		164		(59	)	(36.0	%)		432		416		16		3.8	%
International		76		137		(61	)	(44.5	%)		297		455		(158	)	(34.7	%)
Total	$	8,787	$	8,744	$	43		0.5	%	$	26,287	$	25,593	$	694		2.7	%

Home care revenue. Home care revenue for the three months ended March 31, 2021 was approximately $8,163,000, representing an increase of approximately $329,000, or 4.2%, compared to the same period in fiscal 2020. For the nine months ended March 31, 2021, home care revenue was approximately $24,529,000, representing an increase of approximately $1,534,000, or 6.7%, compared to the same period in fiscal 2020. The revenue increase compared to the prior year periods was primarily due to an increase in referrals and approvals. The increase in referrals compared to the prior year periods was due to the sales team adapting to a hybrid virtual and face-to-face selling model implemented to combat clinic access limitations due to the COVID-19 pandemic, benefits of the CMS waiver on the non-commercial Medicare portion of our home care revenue, and an increase in direct sales representatives.

The CMS waiver benefited the non-commercial Medicare portion of our home care revenue by increasing the number of referrals and the approval percentage for non-covered diagnoses. We believe that our ongoing sales team execution, along with the expected return to pre-COVID-19 levels of patient face-to-face engagement with physicians and clinic access for our sales team, has the potential to mitigate the impact of a CMS waiver expiration, which is currently effective until July 2021.

Institutional revenue. Institutional revenue for the three months ended March 31, 2021 was approximately $443,000, representing a decrease of approximately $166,000, or 27.3%, compared to the same period in fiscal 2020. For the nine months ended March 31, 2021, institutional revenue was approximately $1,029,000, a decrease of approximately $698,000, or 40.4%, compared to the same period in fiscal 2020. The decrease in the current year periods was primarily due to the continued impact of COVID-19 on hospital purchasing activity.

Home care distributor revenue. Home care distributor revenue for the three months ended March 31, 2021 was approximately $105,000, representing a decrease of approximately $59,000, or 36.0%, compared to the same period in fiscal 2020. For the nine months ended March 31, 2021, home care distributor revenue was approximately $432,000, an increase of approximately $16,000, or 3.8%, compared to the same period in fiscal 2020. We began selling to home medical equipment distributors during the three months ended September 30, 2019, who in turn sell our SmartVest System in the U.S. home care market.

International revenue. International revenue for the three months ended March 31, 2021 was approximately $76,000, representing a decrease of approximately $61,000, or 44.5%, compared to the same period in fiscal 2020. For the nine months ended March 31, 2021, international revenue was approximately $297,000, a decrease of approximately $158,000, or 34.7%, compared to the same period in fiscal 2020. International sales are affected by the timing of international distributor purchases that can cause significant fluctuations in reported revenue on a quarterly basis.

Gross profit

Gross profit increased to approximately $6,701,000, or 76.3% of net revenues, for the three months ended March 31, 2021, from approximately $6,594,000, or 75.4% of net revenues, in the same period in fiscal 2020. Gross profit increased to approximately $20,374,000, or 77.5% of net revenues, for the nine months ended March 31, 2021, from approximately $19,611,000, or 76.6% of net revenues, in the same period in fiscal 2020. The increase in gross profit percentage compared to the prior year periods was primarily due to a higher mix of home care revenue and a favorable mix of Medicare within the home care channel.

Operating expenses

Selling, general and administrative expenses. Selling, general and administrative (“SG&A”) expenses were approximately $6,051,000 and $16,490,000 for the three and nine months ended March 31, 2021, respectively, representing increases of approximately $763,000 and $1,342,000, or 14.4% and 8.9%, respectively, compared to the same periods in the prior year.

Payroll and compensation-related expenses were approximately $3,838,000 and $10,569,000 for the three and nine months ended March 31, 2021, respectively, representing increases of approximately $561,000 and $1,118,000, or 17.1% and 11.8%, respectively, compared to the same periods in the prior year. The increase in the current year periods was primarily due to a higher average number of sales and marketing personnel, increased temporary resources to assist with systems infrastructure investments, and increased incentive payments on higher home care revenue. Field sales employees totaled 48, of which 39 were direct sales, as of March 31, 2021, compared to 44 as of March 31, 2020, of which 37 were direct sales. We commenced recruiting for four additional direct field sales employees in April 2021.

Travel, meals and entertainment expenses were approximately $440,000 and $1,270,000 for the three and nine months ended March 31, 2021, respectively, representing decreases of approximately $85,000 and $397,000, or 16.2% and 23.8%, respectively, compared to the same periods in the prior year. The decrease in the current year periods was primarily due to travel reductions in connection with COVID-19.

Total discretionary marketing expenses were approximately $348,000 and $853,000 for the three and nine months ended March 31, 2021, respectively, representing an increase of approximately $126,000 and $385,000, or 56.8% and 82.3%, respectively, compared to the same periods in the prior year. The increase in the current year periods was primarily due to a direct-to-consumer marketing campaign that began in May 2020 and a comprehensive market research project.

Professional fees were approximately $700,000 and $1,686,000 for the three and nine months ended March 31, 2021, respectively, representing an increase of approximately $124,000 and $212,000, or 21.5% and 14.4%, respectively, compared to the same periods in the prior year. Professional fees are primarily for services related to legal costs, shareowner services and reporting requirements, information technology technical support and consulting fees. The increase in the current year periods was primarily due to higher legal fees, annual fees associated with a new human resources platform, increased investment in leadership development training, and fees associated with the implementation of our new revenue cycle management software. We expect to make continued investments in our systems infrastructure over the next year, including an enterprise resources planning software implementation.

Research and development expenses. Research and development (“R&D”) expenses were approximately $407,000 and $1,396,000 for the three and nine months ended March 31, 2021, respectively, representing increases of approximately $15,000 and $762,000, or 3.8% and 120.2%, respectively, compared to the same periods in the prior year. The increase in the current year periods was primarily due to next generation platform development activities. R&D expenses were approximately 4.6% and 5.3% of revenue for the three and nine months ended March 31, 2021, respectively, and we expect R&D investment to remain in a similar range through calendar 2021.

Interest income, net

Net interest income for the three and nine months ended March 31, 2021 was approximately $10,000 and $29,000, respectively, compared to approximately $34,000 and $111,000, respectively, in the comparable prior year periods. The decrease in the current year periods was primarily due to lower rates earned on our cash deposits.

Income tax expense

Estimated income tax expense for the nine months ended March 31, 2021 included a $37,000 discrete tax benefit as a result of lower federal and state taxes than what was originally estimated in our fiscal 2020 tax provision and a $32,000 discrete tax benefit related to the exercise of stock options. The net impact of these discrete events decreased the estimated effective tax rates by 2.7% during the nine months ended March 31, 2021.

Estimated income tax expense for the nine months ended March 31, 2020 included a $30,000 discrete tax expense as a result of higher federal and state taxes than what was originally estimated in our fiscal 2019 tax provision and a $13,000 discrete tax benefit related to the exercise of stock options. The net impact of these discrete events increased the estimated effective tax rates by 0.4% during the nine months ended March 31, 2020.

Net income

Net income for the three and nine months ended March 31, 2021 was approximately $224,000 and $1,962,000, respectively, compared to $653,000 and $2,853,000 for the same periods in the prior year. The decrease in the current year periods was driven by increased strategic investments in SG&A and R&D, partially offset by stronger home care revenue performance and higher gross margin percentage.

Liquidity and Capital Resources

Cash Flows and Sources of Liquidity

Cash Flows from Operating Activities

For the nine months ended March 31, 2021, net cash provided by operating activities was approximately $2,325,000. Cash flows provided by operating activities consisted of net income of approximately $1,962,000, an increase in accounts payable and accrued liabilities of $1,219,000, non-cash expenses of $1,315,000, a decrease in contract assets of $345,000, and a decrease in inventory of $839,000. These cash flows from operating activities were partially offset by an increase in accounts receivable of $3,296,000 and an increase in prepaid expenses and other assets of $69,000. The increase in accounts receivable was primarily due to an increase in the Medicare portion of our home care business, which has a 13-month payment cycle.

Cash Flows from Investing Activities

For the nine months ended March 31, 2021, cash used in investing activities was approximately $208,000. Cash used in investing activities consisted of approximately $105,000 in expenditures for property and equipment and approximately $103,000 in expenditures for patent costs.

Cash Flows from Financing Activities

For the nine months ended March 31, 2021, cash used in financing activities was approximately $95,000, which consisted of approximately $46,000 of cash provided from stock option exercises offset by approximately $141,000 of taxes paid on net share settlements of stock option exercises.

Adequacy of Capital Resources

Our primary working capital requirements relate to adding employees to our sales force and support functions, continuing R&D efforts, IT infrastructure projects, and supporting general corporate needs, including financing equipment purchases and other capital expenditures incurred in the ordinary course of business. Based on our current operational performance, we believe our working capital of approximately $28,050,000 and available borrowings under our existing credit facility will provide adequate liquidity during fiscal 2021.

Effective December 18, 2020, we renewed our credit facility, which provides us with a revolving line of credit. Interest on borrowings on the line of credit accrues at the prime rate (3.25% at March 31, 2021) less 1.00% and is payable monthly. There was no outstanding principal balance on the line of credit as of March 31, 2021 or June 30, 2020. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.00% of eligible accounts receivable, and the line of credit expires on December 18, 2021, if not renewed. At March 31, 2021, the maximum $2,500,000 was available under the line of credit. Payment obligations under the line of credit are secured by a security interest in substantially all of our tangible and intangible assets.

The documents governing our line of credit contain certain financial and nonfinancial covenants that include a minimum tangible net worth of not less than $10,125,000 and restrictions on our ability to incur certain additional indebtedness or pay dividends.

Any failure to comply with these covenants in the future may result in an event of default, which if not cured or waived, could result in the lender accelerating the maturity of our indebtedness, preventing access to additional funds under the line of credit, requiring prepayment of outstanding indebtedness, or refusing to renew the line of credit. If the maturity of the indebtedness is accelerated or the line of credit is not renewed, sufficient cash resources to satisfy the debt obligations may not be available and we may not be able to continue operations as planned. If we are unable to repay such indebtedness, the lender could foreclose on these assets.

For the nine months ended March 31, 2021 and 2020, we spent approximately $105,000 and $753,000, respectively, on property and equipment. We currently expect to finance planned equipment purchases with cash flows from operations or borrowings under our credit facility. We may need to incur additional debt if we have an unforeseen need for additional capital equipment or if our operating performance does not generate adequate cash flows.

Off-Balance Sheet Arrangements

As of March 31, 2021, we had no off-balance sheet arrangements.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this Quarterly Report on Form 10-Q that are not statements of historical fact should be considered forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include, but are not limited to, statements regarding: the expected impact of the COVID-19 pandemic on our business; our business strategy, including our intended level of investment in R&D and marketing activities; our expectations with respect to earnings, gross margins and sales growth, industry relationships, marketing strategies and international sales; estimated sizes of markets into which our products are or may be sold; our business strengths and competitive advantages; our ability to grow additional sales distribution channels; our intent to retain any earnings for use in operations rather than paying dividends; our expectation that our products will continue to qualify for reimbursement and payment under government and private insurance programs; our intellectual property plans and practices; the expected impact of applicable regulations on our business; our beliefs about our manufacturing processes; our expectations and beliefs with respect to our employees and our relationships with them; our belief that our current facilities are adequate to support our growth plans; our expectations with respect to ongoing compliance with the terms of our credit facility; our expectations regarding the ongoing availability of credit and our ability to renew our line of credit; enhancements to our products and services; expected excise tax exemption for the SmartVest System; and our anticipated revenues, expenses, capital requirements and liquidity. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “ongoing,” “plan,” “potential,” “project,” “should,” “target,” “will,” “would,” and similar expressions, including the negative of these terms, are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Although we believe these forward-looking statements are reasonable, they involve risks and uncertainties that may cause actual results to differ materially from those projected by such statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results or our industry’s actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements.

Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, the following:

●

the duration, extent and severity of the COVID-19 pandemic, including its effects on our business, operations and employees as well as its impact on our customers and distribution channels and on economies and markets more generally;

●

the competitive nature of our market;

●

changes to Medicare, Medicaid, or private insurance reimbursement policies;

●

changes to state and federal health care laws;

●

changes affecting the medical device industry;

●

our ability to develop new sales channels for our products such as the home care distributor channel;

●

our need to maintain regulatory compliance and to gain future regulatory approvals and clearances;

●

new drug or pharmaceutical discoveries;

●

general economic and business conditions;

●

our ability to renew our line of credit or obtain additional credit as necessary;

●

our ability to protect and expand our intellectual property portfolio;

●

the risks associated with expansion into international markets; and

●

the risks associated with our planned sales force expansion.

This list of factors is not exhaustive, however, and these or other factors, many of which are outside of our control, could have a material adverse effect on us and our results of operations. Therefore, you should consider these risk factors with caution and form your own critical and independent conclusions about the likely effect of these risk factors on our future performance. Forward-looking statements speak only as of the date on which the statements are made, and we undertake no obligation, and expressly disclaim any such obligation, to update any forward-looking statement for any reason other than as required by law, even if new information becomes available or other events occur in the future. You should carefully review the disclosures and the risk factors described in this and other documents we file from time to time with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for fiscal 2020. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth herein.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide disclosure pursuant to this Item.

Item 4.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our principal executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act, as of the end of the period subject to this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the date of such evaluation to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

Changes to Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings.

Occasionally, we may be party to legal actions, proceedings, or claims in the ordinary course of business, including claims based on assertions of patent and trademark infringement. Corresponding costs are accrued when it is probable that loss will be incurred and the amount can be precisely or reasonably estimated. We are not aware of any undisclosed actual or threatened litigation that would have a material adverse effect on our financial condition or results of operations.

Item 1A.

Risk Factors.

As a smaller reporting company, we are not required to provide disclosure pursuant to this Item.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.

Defaults Upon Senior Securities.

None.

Item 4.

Mine Safety Disclosures.

None.

Item 5.

Other Information.

None.

Item 6.

Exhibits.

Exhibit Number	Description	Method of Filing
3.1	Composite Articles of Incorporation, as amended through November 8, 2010 (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the fiscal year ended June 30, 2015)	Incorporated by Reference

3.2	Amended and Restated Bylaws, effective September 29, 2020 (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed September 29, 2020)	Incorporated by Reference

31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically

31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically

32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished Electronically

32.2	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished Electronically

101	Financial statements from the Quarterly Report on Form 10-Q for the period ended March 31, 2021, formatted in XBRL: (i) Condensed Balance Sheets, (ii) Condensed Statements of Operations, (iii) Condensed Statements of Cash Flows, (iv) Condensed Statements of Shareholders’ Equity, and (v) Notes to Condensed Financial Statements	Filed Electronically

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		ELECTROMED, INC.

		/s/ Kathleen S. Skarvan
Date:	May 11, 2021	Kathleen S. Skarvan, President and Chief Executive Officer (duly authorized officer)

		/s/ Michael J. MacCourt
Date:	May 11, 2021	Michael J. MacCourt, Chief Financial Officer (principal financial officer and principal accounting officer)

SEC Form 10-Q filed by Electromed, Inc.